Gopal P. Jadhav, PhD

Gopal P. Jadhav, PhD

Gopal P. Jadhav, PhD

Assistant Professor
Board Membership, Serving as a member on a sub-committee of the Laboratory Safety Committee to evaluate software for maintaining and reporting chemical inventory at Creighton.
School of Medicine, Omaha Campus

Expertise/Specializations

  • Synthetic organic chemistry: Hands on experience in modern synthetic organic chemistry like multi-step syntheses of drug like molecules, heterocycles, peptides, etc., parallel synthesis using Radley’s. Independent planning and execution of SAR.
  • Analytical techniques: Hands on modern separations techniques. Adept at using NMR, HPLC (analytical, prep., normal, RP, ion-exchange, size-exclusion), GC-, LC-MS, UV/VIS, IR, CD, detection based on fluorescence.
  • Hands on Molecular modelling softwares: Schrodinger Maestro (GLIDE, Homology Modeling, Epik, Ligprep, Protprep) Sybyl7.3, 8.0, Pymol, Database search (Zinc) and processing, Docking (GOLD, Glide, Openeye), Homology modelling, SciFinder, Beilstein, MDL/ISIS
  • Bioassay techniques: Advanced skills in Splenocyte proliferation assays in murine leukocytes and human blood monocytes (immune assay) and Bioluminescence induction assay using luminometer (microbiological assay).

Academic Appointments

Department

  • Pharmacology and Neuroscience

Position

  • Assistant Professor

Teaching Activity

  • CTS 719 (Fall 2017) DRUG DISCOVERY AND TRANSLATION OF RESEARCH INNOVATION TO COMMERCIAL ENTITIES: ACADEMIC ENTREPRENEURSHIP (3)

Biography

After obtaining a Bachelor and Masters degrees in pharmacy from the Pune University (India) in 1998, Dr Gopal spent a year working as a synthetic chemist and three years working as Lecturer of Medicinal chemistry in India, before undertaking a PhD at the University of Nottingham, UK. He completed Ph D under the supervision of Dr S R Chhabra, Prof. Peter Fischer, Prof. David Pritchard and Prof. Barrie Kellam and  continued to work for five years as post-doctoral research fellow on following projects.
1) Cancer Research project funded by BBSRC, UK, focusing on the work involving Computer aided designing and synthesis of small chemical molecules as inhibitors of pRb-E7 interactions. 

2) Seeding Drug Discovery project funded by Wellcome Trust, UK focusing on the Synthesis of novel chemicals and lead optimization of new highly selective beta-blockers in the management of cardiovascular disorders.

3) project funded by MRC, UK, focusing on Development of Inhibitors of Human deadnylase enzyme, new treatment for the Osteoporosis.

Subsequently, Dr Gopal spent one and a half years as a senior research scientist at the RD Alternative Discovery & Development, GlaxoSmithKline (Madrid Trescants, Spain) where he worked on collaborative-project with Prof. Michael Pollastri (Northeastern University, USA) and Prof. Harry De Koning (University of Glasgow, UK), involving structural optimization of GSK675728A, hPDE4 inhibitor to generate novel pharmacophore(s) as potent TbrPDE1 inhibitors that are selective over hPDEs in the management of African sleeping sickness (CNS disorder). 
Dr Gopal joined Creighton University in June 2016 as Postdoctoral research fellow and promoted to Assistant Professor of medicinal chemistry in early 2017. He is working as assistant professor within the school of Medicine under the leadership of Dr Peter Abel.

Publications and Presentations

Articles

  • , Chapter 10, 237-250
  • , 2 (1), 1007
  • , 5 (3), 45
  • , 23 (4), 875
  • , 31
  • , 57(6), 2813-2819
  • , 42(5), 1–10
  • , 54, 3348– 3359
  • , 36(8), 505-508
  • , 36(8), 505-508
  • , 35(8), 475-480
  • , 35(11), 718-720
  • , 60(4), 246-248

Editing and Reviews

Presentations

Research and Scholarship

Research and Scholarship Interests

  • Drug discovery in Cardiac and cardiovascular disorders
    Drug discovery in immuno and inflammatory disorders
    Drug discovery in Quorum sensing
    Drug discovery in Highly neglected diseases
     

Current Research Projects

  • Dr. Jadhav is working on the design and development of novel inhibitors of triggering receptor expressed on myeloid cells–1 (TREM-1), in the management of life threatening sepsis and CVD. This interdisciplinary research warrants use of computer aided drug design approach to develop and synthesis of small drug like molecules. Current inhibitors are peptide molecules (LR-17 and LR-12), that have a very short half-life and possibly with multiple targets.

    Molecular docking and HTS assay techniques will be employed to identify from from a library of 80000 diverse chemical molecules. These hits will be tested for TREM-1 inhibitory potential to identify new chemical lead(s). Lead(s) will be recruited for extensive chemical modifications (SAR- development) in order to optimize potency, toxicity and druggability.  

Awards and Honors

  • , 2019
  • Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease, 2015
  • Novel Ether Linked Compounds and Improved Treatments for Cardiac and Cardiovascular Disease, 2012
  • PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES, 2012